US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Astellas Pharma, Inc.

16.20

+0.30001.89%

Pre-market: 16.200.00000.00%08:02 EST

Volume:272.00K

Turnover:4.32M

Market Cap:29.00B

PE:217.88

High:16.20

Open:15.71

Low:15.71

Close:15.90

52wk High:16.95

52wk Low:8.37

Shares:1.79B

Float Shares:1.75B

Volume Ratio:1.66

T/O Rate:0.02%

Dividend:0.51

Dividend Rate:3.16%

EPS(TTM):0.0744

EPS(LYR):0.0628

ROE:19.82%

ROA:7.38%

PB:2.55

PE(LYR):257.79

Loading ...

Overview Company News Filings

Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV

Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities

Press Release: Astellas Announces Top Management Personnel Change

China Convicts Employee of Japanese Drugmaker of Spying -- WSJ

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":16.2,"timestamp":1771448400000,"preClose":15.9,"halted":0,"volume":271996,"hourTrading":{"tag":"盘前","latestPrice":16.2,"preClose":16.2,"latestTime":"08:02 EST","volume":0,"amount":0,"timestamp":1771506120000,"change":0,"changeRate":0,"amplitude":0},"delay":15,"changeRate":0.01886792452830182,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"Pre-Mkt","change":0.3,"latestTime":"02-19 08:02:00 EST Delay","open":15.71,"high":16.2,"low":15.71,"amount":4318325.641800002,"amplitude":0.030818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771511400000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":16.2,"volumeRatio":1.6607765228461144},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"7.38%","roe":"19.82%","lyrEps":0.062841,"volumeRatio":1.6607765228461144,"shares":1790310070,"dividePrice":0.5123,"high":16.2,"amplitude":0.030818,"preClose":15.9,"low":15.71,"week52Low":8.37,"pbRate":"2.55","psRate":"2.18","week52High":16.95,"institutionHeld":0,"latestPrice":16.2,"eps":0.074352,"divideRate":0.031623,"volume":271996,"delay":15,"ttmEps":0.074352,"open":15.71,"prevYearClose":13.29,"prevWeekClose":16.49,"prevMonthClose":13.86,"prevQuarterClose":13.29,"fiveDayClose":16.38,"twentyDayClose":13.99,"sixtyDayClose":12.225},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758517200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592971859","title":"Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971859","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592971859?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:38","pubTimestamp":1765975080,"startTime":"0","endTime":"0","summary":"A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer.The companies on Wednesday said Merck's Keytruda coupled with Padcev from Pfizer and Astellas showed significantly improved survival for patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.The study met its primary endpoint, demonstrating clinically meaningful and statistically significant improvements in event-free survival, as well as in overall survival, a key secondary endpoint, the companies said.Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, said they plan to discuss the study results with global health authorities for potential regulatory filings.Merck in 2019 inked a deal to evaluate the combination of its block","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1116320737.USD","IE00BLSP4452.SGD","LU0106261372.USD","BK4007","LU0098860793.USD","LU0225284248.USD","LU0965509283.SGD","LU1989771016.USD","BK4550","LU1983299246.USD","LU1037948541.HKD","LU1585245621.USD","LU0320765489.SGD","IE00B19Z3581.USD","LU1941712348.USD","LU1934455194.USD","IE00B1BXHZ80.USD","LU0265550359.USD","BK4534","LU0130517989.USD","LU0965508806.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU1069347547.HKD","LU0122379950.USD","LU1116320901.HKD","IE00B19Z3B42.SGD","LU1061106388.HKD","LU0058720904.USD","LU2023250843.SGD","IE00BJT1NW94.SGD","LU1941712264.USD","LU0965509010.AUD","LU2361044949.HKD","LU2361044865.SGD","LU2112291526.USD","IE0009355771.USD","SG9999002232.USD","IE0002270589.USD","SG9999002224.SGD","LU1894683348.USD","LU1934455863.HKD","BK4585","LU2360032135.SGD","LU2324357040.USD","LU0006306889.USD","BK4592","SG9999003800.SGD","BK4588","BK4559","SG9999001176.USD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","LU0648001328.SGD","LU1571399168.USD","LU2461242641.AUD","IE00B2B36J28.USD","LU1162221912.USD","LU0203347892.USD","SG9999014542.SGD","LU0456855351.SGD","LU2125154935.USD","LU0861579265.USD","LU0477156953.USD","LU0234572021.USD","SG9999014575.USD","LU0225771236.USD","LU0211331839.USD","LU0985481810.HKD","SG9999011175.SGD","LU2023250504.SGD","LU0266013472.USD","PFE","LU0965509101.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU1883839398.USD","SG9999001176.SGD","BK4533","LU0320765646.SGD","LU1699723380.USD","LU1917777945.USD","LU0306807586.USD","LU1989772923.USD","BK4568","LU0203345920.USD","SG9999014567.USD","LU2106854487.HKD","LU2468319806.SGD","LU0306806265.USD","LU1974910355.USD","LU2089984988.USD","LU2361045086.USD","SG9999015341.SGD","LU0985320562.USD","LU1894683264.USD","BK4599","IE000M9KFDE8.USD","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4581","LU1989772840.SGD","LU0868494617.USD","MRK","LU0321505868.SGD","IE0002141913.USD","LU0289739699.SGD","LU0265550946.USD","LU0170899867.USD","LU1201861249.SGD","LU1929549753.HKD","LU1066051811.HKD","BK4516","ALPMY","LU1066051498.USD","SG9999015358.SGD","LU0980610538.SGD","SG9999001440.SGD","LU0238689110.USD","LU0070302665.USD","LU1066051225.USD","LU1035773651.USD","LU1066053197.SGD","SG9999013999.USD","LU1291159041.SGD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","LU1093756325.SGD","SG9999014559.SGD","LU1023059063.AUD","LU2125154778.USD","LU1430594728.SGD","LU1934455277.USD","LU0208291251.USD","LU0130102774.USD","LU1093756168.USD"],"gpt_icon":1},{"id":"2585622140","title":"FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585622140","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585622140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:52","pubTimestamp":1763747520,"startTime":"0","endTime":"0","summary":"The Food and Drug Administration approved Merck's Keytruda in combination with Astellas's Padcev to treat certain adults with muscle invasive bladder cancer .The FDA said Friday it has approved the drug combination as a treatment for before and after bladder-removal surgery in adult MIBC patients who are ineligible for cisplatin, a chemotherapy medication.A recent trial demonstrated statistically significant improvements in event-free survival and overall survival for patients with previously untreated MIBC who were treated with the drug combination before and after bladder-removal surgery and pelvic lymph node dissection, compared with surgery alone, the FDA said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948897.HKD","SG9999015341.SGD","BK4533","LU1989771016.USD","LU1116320901.HKD","SG9999001440.SGD","BK4585","LU0203345920.USD","LU0238689110.USD","LU1291159041.SGD","MRK","LU1699723380.USD","LU2461242641.AUD","SGXZ57979304.SGD","LU1093756168.USD","LU1035773651.USD","IE00BJT1NW94.SGD","ALPMY","LU0208291251.USD","LU2468319806.SGD","SG9999014567.USD","LU0861579265.USD","IE00B2B36J28.USD","LU1929549753.HKD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU0265550946.USD","LU1571399168.USD","LU1974910355.USD","SG9999001176.USD","LU1023059063.AUD","SG9999015358.SGD","IE0002141913.USD","LU2106854487.HKD","LU0965509283.SGD","IE000M9KFDE8.USD","LU0320765489.SGD","IE0009355771.USD","SG9999002224.SGD","LU1983299246.USD","IE00BBT3K403.USD","LU2324357040.USD","BK4516","LU0234572021.USD","IE00BLSP4239.USD","LU1989772840.SGD","IE00B4R5TH58.HKD","LU1066051811.HKD","LU2023250504.SGD","LU1941712264.USD"],"gpt_icon":0},{"id":"2576176006","title":"Astellas, Pfizer announces results from Phase 3 EV-303 trial for PADCEV","url":"https://stock-news.laohu8.com/highlight/detail?id=2576176006","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576176006?lang=en_us&edition=fundamental","pubTime":"2025-10-20 05:20","pubTimestamp":1760908807,"startTime":"0","endTime":"0","summary":"Astellas Pharma (ALPMY) and Pfizer (PFE) announced positive results from the Phase 3 EV-303 clinical trial for PADCEV, a Nectin-4 directed antibody...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astellas-pfizer-announces-results-from-phase-3-ev-303-trial-for-padcev-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALPMY","IE000M9KFDE8.USD","LU0868494617.USD","LU0058720904.USD","BK4592","IE0002270589.USD","SG9999002232.USD","BK4534","LU0170899867.USD","LU1066051498.USD","SG9999011175.SGD","BK4550","LU1057294990.SGD","SGXZ57979304.SGD","BK4568","LU0321505868.SGD","SG9999003800.SGD","BK4533","PFE","IE00B19Z3581.USD","BK4007","SG9999001176.SGD","LU1883839398.USD","BK4599","LU0306806265.USD","LU0225771236.USD","LU0985481810.HKD","LU1894683348.USD","BK4585","LU0225284248.USD","SG9999001176.USD","SG9999013999.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0321505439.SGD","SG9999002224.SGD","BK4588","IE00BLSP4452.SGD","BK4581","IE00BBT3K403.USD","LU1894683264.USD","LU1066053197.SGD","LU0456855351.SGD","LU0122379950.USD","LU0306807586.USD","LU0289739699.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2575263346","title":"Yomiuri: Astellas Pharma Offers Leadership Training to Assist Patient Group Activities","url":"https://stock-news.laohu8.com/highlight/detail?id=2575263346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575263346?lang=en_us&edition=fundamental","pubTime":"2025-10-14 14:19","pubTimestamp":1760422740,"startTime":"0","endTime":"0","summary":"Major Japanese pharmaceutical firm Astellas Pharma Inc. in Tokyo is offering unique training to support the development of personnel involved in patient group management to establish stable organizational foundations and sustain their activities.In fiscal 2021, it launched the leadership training program to equip participants with the knowledge and skills necessary for management. Participants can attend five free lectures per year, given by external instructors such as university faculty and human resource development consultants.The lectures cover topics like enhancing communication skills and approaches to organizational management. Over the past four events, a total of 72 participants from 51 groups have attended. This has led to tangible outcomes, such as participants presenting their activities at academic conferences gathering domestic specialist physicians and establishing connections with overseas patient groups.This article is from The Yomiuri Shimbun. Neither Dow Jones Newsw","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALPMY","BK4007"],"gpt_icon":0},{"id":"2571806997","title":"Press Release: Astellas Announces Top Management Personnel Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2571806997","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571806997?lang=en_us&edition=fundamental","pubTime":"2025-09-29 14:00","pubTimestamp":1759125600,"startTime":"0","endTime":"0","summary":"TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced the following changes to its Top Management structure, effective October 1, 2025.Nick Eshkenazi, current Chief Digital & Transformation Officer , will leave Astellas on September 30, 2025. Consequently, effective October 1, 2025, the position of CDTO will be removed from Top Management, with both Digital and Transformation functions being integrated into the Strategy function, led by Adam Pearson, the Chief Strategy Officer .In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from tho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","CRDO","BK4595","BK4007","LU1861220033.SGD","LU2360107168.USD","ALPMY","CFO","LU0053671581.USD","BK4516","CEO","LU1861215975.USD","BK4585","BK4023","BK4596","BK4588","STRK","LU2290526834.HKD","BK4600"],"gpt_icon":1},{"id":"2551143254","title":"China Convicts Employee of Japanese Drugmaker of Spying -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2551143254","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551143254?lang=en_us&edition=fundamental","pubTime":"2025-07-16 15:39","pubTimestamp":1752651540,"startTime":"0","endTime":"0","summary":"HONG KONG -- A court in Beijing sentenced a Japanese pharmaceutical executive on Wednesday to 3 1/2 years in prison on charges of espionage, Japan said, in a case that heightened tensions between the two countries and concerns about legal risks for foreign businesspeople in China.The executive, Hiroshi Nishiyama, was a veteran employee in China for Astellas Pharma who was first detained in March 2023 and accused of espionage, though no details of his alleged wrongdoing were released. China has an extensive definition of national security that has grown further following changes to its law against espionage in 2023.Tensions between China and Japan have flared in recent years over issues including Japan's release of water from the Fukushima Daiichi nuclear power plant into the sea, the increasing presence of Chinese coast guard and naval vessels near Japan and lingering grievances over Imperial Japan's occupation of China in the 1930s and 40s.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALPMY"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}